Validation of profile for the omission of local adjuvant radiotherapy (POLAR) in a meta-analysis of three randomized controlled trials of breast conserving surgery +/- radiotherapy

The POLAR signature is a genetic classifier to define benefit of breast cancer radiotherapy. In this interview prof. dr. Per Karlsson from the Sahlgrenska Academy, Gothenburg, Sweden explained how clinical validation was performed via a patient-level meta-analysis of node-negative patients with ER+ / HER2-tumors from 3 clinical trials. The performance of the POLAR signature as a prognostic factor for locoregional recurrence in the absence of RT and as a predictor of benefit from radiotherapy following breast conserving surgery, was evaluated. He concludes with a glimpse into the future.